ZOMETA® (Zoledronic Acid) Is Bone Targeted Therapy For Prostate Cancer Patients With Bone Metastases

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA
Prostate Cancer
Threat of SREs

Page

1 2

Bone metastases remain a major concern for patients with prostate cancer

65% to 75% of patients with advanced prostate cancer will develop bone metastases,
which may lead to bone complications or SREs^1*
49% of patients with prostate cancer and bone metastases will experience an SRE
without treatment²

*SREs are generally defined as pathologic fractures, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcemia.³

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.